These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 25078559)
1. Neoadjuvant Chemotherapy in Breast Cancer Patients Induces miR-34a and miR-122 Expression. Frères P; Josse C; Bovy N; Boukerroucha M; Struman I; Bours V; Jerusalem G J Cell Physiol; 2015 Feb; 230(2):473-81. PubMed ID: 25078559 [TBL] [Abstract][Full Text] [Related]
2. miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Kastl L; Brown I; Schofield AC Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894 [TBL] [Abstract][Full Text] [Related]
3. MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer. Raychaudhuri M; Bronger H; Buchner T; Kiechle M; Weichert W; Avril S Breast Cancer Res Treat; 2017 Apr; 162(3):511-521. PubMed ID: 28181130 [TBL] [Abstract][Full Text] [Related]
4. Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer. Zhang Z; Zhang H; Li C; Xiang Q; Xu L; Liu Q; Pang X; Zhang W; Zhang H; Zhang S; Duan X; Liu Y; Cui Y Thorac Cancer; 2021 Dec; 12(24):3396-3406. PubMed ID: 34751517 [TBL] [Abstract][Full Text] [Related]
5. Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment. Al-Khanbashi M; Caramuta S; Alajmi AM; Al-Haddabi I; Al-Riyami M; Lui WO; Al-Moundhri MS PLoS One; 2016; 11(4):e0152032. PubMed ID: 27064979 [TBL] [Abstract][Full Text] [Related]
6. miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer. Hu Y; Qiu Y; Yagüe E; Ji W; Liu J; Zhang J Cell Death Dis; 2016 Jun; 7(6):e2291. PubMed ID: 27362808 [TBL] [Abstract][Full Text] [Related]
7. Altered levels of the onco-microRNA 21 and the tumor-supressor microRNAs 143 and 145 in advanced rectal cancer indicate successful neoadjuvant chemoradiotherapy. Drebber U; Lay M; Wedemeyer I; Vallböhmer D; Bollschweiler E; Brabender J; Mönig SP; Hölscher AH; Dienes HP; Odenthal M Int J Oncol; 2011 Aug; 39(2):409-15. PubMed ID: 21567082 [TBL] [Abstract][Full Text] [Related]
8. Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients. Kassem NM; Makar WS; Kassem HA; Talima S; Tarek M; Hesham H; El-Desouky MA Asian Pac J Cancer Prev; 2019 Sep; 20(9):2749-2755. PubMed ID: 31554373 [TBL] [Abstract][Full Text] [Related]
9. miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression. Corcoran C; Rani S; O'Driscoll L Prostate; 2014 Sep; 74(13):1320-34. PubMed ID: 25053345 [TBL] [Abstract][Full Text] [Related]
10. Potential molecular mechanisms for improved prognosis and outcome with neoadjuvant chemotherapy prior to laparoscopical radical hysterectomy for patients with cervical cancer. Sun H; Xin J; Lu Z; Wang N; Liu N; Guo Q Cell Physiol Biochem; 2013; 32(5):1528-40. PubMed ID: 24335178 [TBL] [Abstract][Full Text] [Related]
11. MiRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity. Xue J; Chi Y; Chen Y; Huang S; Ye X; Niu J; Wang W; Pfeffer LM; Shao ZM; Wu ZH; Wu J Oncogene; 2016 Jan; 35(4):448-58. PubMed ID: 25867061 [TBL] [Abstract][Full Text] [Related]
12. miRNA expression in breast cancer varies with lymph node metastasis and other clinicopathologic features. Wang B; Li J; Sun M; Sun L; Zhang X IUBMB Life; 2014 May; 66(5):371-7. PubMed ID: 24846313 [TBL] [Abstract][Full Text] [Related]
13. Dynamics of circulating microRNAs as a novel indicator of clinical response to neoadjuvant chemotherapy in breast cancer. Zhu W; Liu M; Fan Y; Ma F; Xu N; Xu B Cancer Med; 2018 Sep; 7(9):4420-4433. PubMed ID: 30099860 [TBL] [Abstract][Full Text] [Related]
14. Age-related microRNAs in older breast cancer patients: biomarker potential and evolution during adjuvant chemotherapy. Dalmasso B; Hatse S; Brouwers B; Laenen A; Berben L; Kenis C; Smeets A; Neven P; Schöffski P; Wildiers H BMC Cancer; 2018 Oct; 18(1):1014. PubMed ID: 30348127 [TBL] [Abstract][Full Text] [Related]
15. Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer. Bovy N; Blomme B; Frères P; Dederen S; Nivelles O; Lion M; Carnet O; Martial JA; Noël A; Thiry M; Jérusalem G; Josse C; Bours V; Tabruyn SP; Struman I Oncotarget; 2015 Apr; 6(12):10253-66. PubMed ID: 25860935 [TBL] [Abstract][Full Text] [Related]
16. The role of miRNAs in drug resistance and prognosis of breast cancer formalin-fixed paraffin-embedded tissues. Chen X; Lu P; Wang DD; Yang SJ; Wu Y; Shen HY; Zhong SL; Zhao JH; Tang JH Gene; 2016 Dec; 595(2):221-226. PubMed ID: 27746365 [TBL] [Abstract][Full Text] [Related]
17. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial. Müller V; Gade S; Steinbach B; Loibl S; von Minckwitz G; Untch M; Schwedler K; Lübbe K; Schem C; Fasching PA; Mau C; Pantel K; Schwarzenbach H Breast Cancer Res Treat; 2014 Aug; 147(1):61-8. PubMed ID: 25086636 [TBL] [Abstract][Full Text] [Related]
18. Circulating miR-34a levels are reduced in colorectal cancer. Nugent M; Miller N; Kerin MJ J Surg Oncol; 2012 Dec; 106(8):947-52. PubMed ID: 22648208 [TBL] [Abstract][Full Text] [Related]
19. Hyaluronic acid-chitosan nanoparticles for co-delivery of MiR-34a and doxorubicin in therapy against triple negative breast cancer. Deng X; Cao M; Zhang J; Hu K; Yin Z; Zhou Z; Xiao X; Yang Y; Sheng W; Wu Y; Zeng Y Biomaterials; 2014 May; 35(14):4333-44. PubMed ID: 24565525 [TBL] [Abstract][Full Text] [Related]
20. Analysis of serum genome-wide microRNAs for breast cancer detection. Wu Q; Wang C; Lu Z; Guo L; Ge Q Clin Chim Acta; 2012 Jul; 413(13-14):1058-65. PubMed ID: 22387599 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]